| Control group | S-AOM group | L-AOM group | |||
---|---|---|---|---|---|---|
Normal gland | Pre-neoplastic lesion | Adenoma | Carcinoma in situ | Carcinoma | Serosal metastatic carcinoma | |
βA-subunit | 215.5 ± 31.1 | 296.8 ± 34.4b | 255.1 ± 29.3a,c | 313.3 ± 22.2b,d | 334.1 ± 27.2b,c,d,e | 363.7 ± 34.3b,c,d,e,f |
βB-subunit | 173.7 ± 28.7 | 113.4 ± 29.2b | 227.2 ± 33.2a,c | 129 ± 31.4b,d | 122.8 ± 25.5b,c,d | 73.7 ± 21 .9b,c,d,e,f |
ACTRIIA | 201.1 ± 26 | 137.2 ± 28.3b | 234.7 ± 31.7a,c | 103.3 ± 28.3b,c,d | 93.4 ± 22.2b,c,d | 68.8 ± 23.3b,c,d,e,f |
ACTRIIB | 116.6 ± 26.7 | 261.8 ± 37.7b | 277.6 ± 31.6b | 311.4 ± 22.8b,c,d | 321.3 ± 28.9b,c.d | 352.4 ± 27.6b,c,d,e,f |
p-Smad2 | 192.4 ± 29.5 | 137.1 ± 26.8b | 88.8 ± 21.7b,c | 79.6 ± 25.3b.c | 78.5 ± 22.9b,c | 81.3 ± 18.8b,c |
p-Smad3 | 272.7 ± 27.6 | 236.5 ± 42.6a | 228.4 ± 47.4b | 142.8 ± 43.6b,c,d | 133.3 ± 39.3b,c,d | 314.7 ± 32.2a,c,d,e,f |
Smad4 | 226.7 ± 29.4 | 163.1 ± 27.2a | 108.8 ± 33.1b,c | 134.5 ± 35.3b,c | 121.4 ± 38.4b,c | 81.3 ± 22.2b,c,d,e,f |
Samds6&7 | 166.8 ± 32.9 | 92.3 ± 21.7b | 132.7 ± 31.3a,c | 115.1 ± 21.3a,d | 89.6 ± 23.3b.d.e | 235.6 ± 42.2b,c,d,e,f |
Follistatin | 237.6 ± 22.2 | 272.3 ± 25.3a | 291.4 ± 24.2b | 317.8 ± 22.3b,c,d | 333.8 ± 35.3b,c,d | 365.8 ± 29.9b,c,d,e |